Anatomical Therapeutic Chemical (ATC) classification [BR:br08303]
L ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS
L01 ANTINEOPLASTIC AGENTS
L01X OTHER ANTINEOPLASTIC AGENTS
L01XX Other antineoplastic agents
L01XX74 Belzutifan
D11954 Belzutifan (JAN/USAN/INN) <US>
USP drug classification [BR:br08302]
Genetic, Enzyme, or Protein Disorder: Replacement, Modifiers, Treatment
Belzutifan
D11954 Belzutifan (JAN/USAN/INN)
Drug groups [BR:br08330]
Metabolizing enzyme substrate
DG01639 CYP2C19 substrate
D11954 Belzutifan
DG01633 CYP3A/CYP3A4 substrate
DG02913 CYP3A4 substrate
D11954 Belzutifan
DG02924 UGT substrate
DG03181 UGT2B17 substrate
D11954 Belzutifan
Target-based classification of drugs [BR:br08310]
Not elsewhere classified
Signaling molecules
Transcription factor
HIF2A
D11954 Belzutifan (JAN/USAN/INN) <US>
New drug approvals in the USA [br08319.html]
New molecular entities and new therapeutic biological products
D11954
New drug approvals in the USA, Europe and Japan [br08328.html]
Approval dates by FDA, EMA and PMDA
D11954
Drug metabolizing enzymes and transporters [br08309.html]
Drug metabolizing enzymes
D11954
Pharmacogenomic biomarkers [br08341.html]
Polymorphisms and mutations affecting drug response
D11954